List of Excipients in Branded Drug NAPROXEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Acella Pharmaceuticals LLC	NAPROXEN	naproxen	42192-619	FD&C YELLOW NO. 6
Acella Pharmaceuticals LLC	NAPROXEN	naproxen	42192-619	FUMARIC ACID
Acella Pharmaceuticals LLC	NAPROXEN	naproxen	42192-619	MAGNESIUM ALUMINUM SILICATE
Acella Pharmaceuticals LLC	NAPROXEN	naproxen	42192-619	METHYLPARABEN
Acella Pharmaceuticals LLC	NAPROXEN	naproxen	42192-619	ORANGE
Acella Pharmaceuticals LLC	NAPROXEN	naproxen	42192-619	PINEAPPLE

Generic Drugs Containing NAPROXEN

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	naproxen	0054-3630	FD&C YELLOW NO. 6
Hikma Pharmaceuticals USA Inc	naproxen	0054-3630	FUMARIC ACID
Hikma Pharmaceuticals USA Inc	naproxen	0054-3630	MAGNESIUM ALUMINUM SILICATE
Hikma Pharmaceuticals USA Inc	naproxen	0054-3630	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	naproxen	0054-3630	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	naproxen	0054-3630	SORBITOL

What are the Most Frequently-Used Excipients in NAPROXEN?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
1	BENZYL ALCOHOL
1	CARBOXYMETHYLCELLULOSE SODIUM
77	CELLULOSE, MICROCRYSTALLINE
1	CI 77491
2	CI 77492

Naproxen Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Naproxen is a mature, low-cost nonsteroidal anti-inflammatory drug (NSAID) with extensive generic competition and no meaningful originator exclusivity barrier in the United States. Commercial opportunity is concentrated in formulation performance, gastrointestinal tolerability, rapid onset, modified release, pediatric delivery, combination products, and differentiated over-the-counter positioning.

The active ingredient is marketed mainly as naproxen and naproxen sodium. Naproxen sodium dissolves more rapidly and is generally used where faster onset is desired. Naproxen is less water-soluble and requires stronger formulation design for rapid-release products. Excipients can improve wetting, disintegration, taste, manufacturability, tablet robustness, and controlled delivery, but they cannot eliminate the dose-related gastrointestinal, renal, and cardiovascular risks inherent to NSAID therapy.

What pharmaceutical products contain naproxen?

Naproxen products are sold in prescription and over-the-counter forms.

Product type	Common strength	Primary commercial use	Formulation priority
Naproxen tablets	250 mg, 375 mg, 500 mg	Prescription pain and inflammatory disorders	Robust immediate release and low cost
Naproxen sodium tablets	275 mg, 550 mg	Prescription pain and inflammation	Faster dissolution and onset
OTC naproxen sodium tablets or caplets	220 mg	Temporary relief of minor pain and arthritis symptoms	Consumer usability, swallowability, packaging
Suspension or liquid products	Product-specific	Pediatric or swallowing-limited patients	Sedimentation control, taste masking, dose accuracy
Extended-release tablets	Product-specific	Once-daily treatment	Release control and tablet integrity
Combination products	Market-specific	Pain, migraine, or cold-related indications	Compatibility, dose flexibility, regulatory positioning
Topical or localized delivery systems	Limited market presence	Localized pain applications	Skin penetration and lower systemic exposure

Naproxen sodium contains the sodium salt of naproxen and has different dose equivalence from naproxen. A 220 mg naproxen sodium tablet is commonly labeled as providing 200 mg naproxen equivalent in the United States. Dose and labeling comparisons must account for the salt form rather than comparing milligram values directly.

Which excipients are most important for naproxen tablets?

The central excipient problem is poor aqueous solubility. Naproxen is generally classified as a low-solubility, high-permeability compound, although biopharmaceutic behavior depends on pH, salt form, particle size, and formulation conditions.

Immediate-release tablet excipient system

A conventional naproxen tablet may use:

• Microcrystalline cellulose as a diluent and compression aid
• Lactose, mannitol, or dibasic calcium phosphate as fillers
• Croscarmellose sodium, sodium starch glycolate, or crospovidone as superdisintegrants
• Povidone or hydroxypropyl cellulose as binders
• Colloidal silicon dioxide as a glidant
• Magnesium stearate, sodium stearyl fumarate, or stearic acid as lubricants
• Film-coating polymers such as hypromellose, polyvinyl alcohol, or methacrylate copolymers
• Titanium dioxide, iron oxides, and approved colorants for identification and appearance

The commercial objective is not simply maximum disintegration. Excessive hydrophobic lubricant or over-lubrication can slow wetting and dissolution. High compression force can reduce porosity and delay tablet breakup. The formulation must balance hardness, friability, disintegration, dissolution, content uniformity, and production speed.

Sodium naproxen formulations

Naproxen sodium is more suitable for immediate-release products because the salt generally dissolves faster than the free acid. The excipient system can therefore emphasize:

• Rapid wetting
• Low lubricant loading
• Fast disintegration
• Moisture control
• Low tablet weight
• Stability against hydrolysis or physical changes

Direct compression is commercially attractive when powder flow, compressibility, and content uniformity are adequate. Wet granulation can improve flow and compression but may add moisture, processing cost, and stability risk. Dry granulation can reduce water exposure while improving manufacturability.

What excipient strategies improve naproxen dissolution?

The highest-value technical strategies use excipients to improve wetting and dispersion without creating a new safety or regulatory burden.

Surfactant-assisted dissolution

Low concentrations of surfactants can improve wetting of naproxen particles. Candidate materials include sodium lauryl sulfate, poloxamers, polysorbates, and certain nonionic surfactants. Selection must address:

• Irritation and gastrointestinal tolerability
• Blend uniformity
• Foam generation
• Lubrication and compression effects
• Compatibility with the active ingredient
• Impact on dissolution across pH conditions

Surfactants are more commercially defensible when they solve a measurable product problem, such as faster dissolution after storage or reduced sensitivity to compression force.

Particle-size engineering

Milling and controlled particle-size distribution can increase surface area. The approach is relatively easy to implement but may create:

• Electrostatic charging
• Poor flow
• Agglomeration
• Segregation
• Dust-control problems
• Greater sensitivity to process conditions

A patent strategy based only on micronized naproxen is vulnerable unless combined with a defined excipient matrix, manufacturing process, dissolution profile, or stability outcome.

Solid dispersions and polymeric carriers

Polyvinylpyrrolidone, copovidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, and related polymers can improve dispersion of naproxen. These systems may be useful for:

• Rapid-release tablets
• Orally disintegrating tablets
• Liquid-filled capsules
• Amorphous solid dispersions
• Supersaturating formulations

The main risks are physical recrystallization, moisture sensitivity, increased tablet size, and scale-up complexity. A solid-dispersion platform has stronger intellectual-property potential than a conventional filler-disintegrant blend, but it requires long-term stability data.

Lipid and self-emulsifying systems

Lipid excipients, medium-chain triglycerides, surfactants, and co-solvents can improve apparent solubilization. They are more relevant to softgels, liquid-filled capsules, and specialized oral systems than to low-cost conventional tablets.

Potential commercial benefits include faster onset and reduced dependence on gastrointestinal pH. Constraints include capsule compatibility, leakage, oxidation, taste, filling equipment, and the need to demonstrate consistent in vitro and in vivo performance.

What excipients support extended-release naproxen?

Extended-release naproxen products can use hydrophilic or hydrophobic matrix systems.

Matrix approach	Typical excipient classes	Commercial advantages	Main risks
Hydrophilic matrix	HPMC, HPC, polyethylene oxide	Simple tablet manufacturing; adjustable release	Food and media sensitivity; gel variability
Hydrophobic matrix	Ethylcellulose, waxes, fatty acids	Strong release control; lower water sensitivity	Incomplete release and manufacturing complexity
Osmotic system	Semipermeable membrane, osmotic agents, pore formers	More predictable release	Higher development and tooling cost
Multiparticulate system	Coated pellets or beads	Flexible dose and release profile	More complex encapsulation and coating
Compression-coated tablet	Barrier polymers and separate drug layers	Delayed or staged release	Larger tablet and process complexity

The commercial case for once-daily naproxen is strongest where adherence, overnight symptom control, or reduced dosing frequency matters. The formulation must avoid dose dumping and must maintain release performance across fed and fasted conditions.

A modified-release product also faces a higher regulatory burden than a standard generic tablet. The sponsor must establish bioequivalence, dose proportionality where applicable, alcohol-induced release behavior, food effects, and performance across relevant dissolution media.

What formulation options address swallowing and pediatric use?

Swallowability is a practical source of differentiation in a mature NSAID market.

Orally disintegrating tablets

Orally disintegrating naproxen products can use mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and taste-masking systems. Naproxen has a bitter taste, so flavoring alone may not be adequate.

Taste-masking options include:

• Polymer coating of drug particles
• Ion-exchange resins
• Cyclodextrin complexes
• Lipid barriers
• pH-modifying microenvironments
• Multiparticulate beads

The key tests are disintegration time, mouthfeel, residual bitterness, dose uniformity, mechanical strength, and moisture stability.

Oral suspensions

A liquid naproxen formulation may use:

• Suspending agents such as xanthan gum, sodium carboxymethylcellulose, or microcrystalline cellulose-based systems
• Wetting agents
• Buffers
• Preservatives
• Sweeteners and flavors
• Antifoaming agents
• Density modifiers

The most important performance criteria are redispersibility, sedimentation rate, syringe dosing accuracy, microbial control, and chemical stability. A suspension can provide commercial value in pediatric, geriatric, and dysphagia populations, but palatability and dosing accuracy are decisive.

What patent opportunities exist for naproxen excipients?

The original compound and basic oral dosage forms are long off-patent. The stronger patent opportunities are formulation-specific.

Potential claim area	Patent strength	Commercial relevance
New naproxen chemical entity	None for new-market entry	Original compound rights are expired
Conventional tablet with standard excipients	Low	Easy generic design-around
Defined dissolution profile	Moderate	Useful if linked to a reproducible formulation
Amorphous dispersion	Moderate to strong	Can create a technically differentiated product
Taste-masked multiparticulates	Moderate	Relevant to pediatric and orally disintegrating products
Extended-release matrix	Moderate	Supports once-daily positioning
Stable liquid suspension	Moderate	Valuable where commercial products are limited
Novel co-crystal or salt	Variable	Requires clinical and regulatory assessment
Manufacturing process with narrow controls	Moderate	Can protect scale-up and quality advantages
Combination product	Variable	Depends on clinical and regulatory differentiation

Patent claims should tie the excipient combination to measurable outcomes, such as dissolution, stability, pharmacokinetic exposure, reduced variability, taste masking, or manufacturing performance. Claims covering only familiar excipients in routine amounts are more vulnerable to obviousness and enablement challenges.

What is the FDA and Orange Book status of naproxen?

Naproxen is an FDA-approved prescription and OTC active ingredient. Prescription products include naproxen and naproxen sodium dosage forms. OTC naproxen sodium products are marketed under the FDA monograph framework for internal analgesic, antipyretic, and antirheumatic products, subject to applicable monograph conditions and labeling requirements.[1][2]

The Orange Book contains approved prescription naproxen and naproxen sodium products and their generic equivalents. The commercial significance of Orange Book listings is limited because:

• The original active-ingredient patents expired decades ago.
• Multiple ANDA products compete on price.
• Current differentiation usually depends on formulation, dosage form, manufacturing reliability, supply, or branding.
• Formulation patents matter only if listed for the relevant reference product and enforceable against the proposed generic.

Naproxen products do not face biosimilar competition because naproxen is a small-molecule drug, not a biologic. The applicable competitive pathway is the ANDA process, not the 351(k) biosimilar pathway.

When does naproxen lose exclusivity?

Naproxen lost core small-molecule exclusivity long ago. The original compound, conventional tablet, and basic salt-form opportunities are commercially generic.

Exclusivity category	Naproxen position
New chemical entity exclusivity	Expired
Original compound patents	Expired
Basic naproxen tablet patents	Expired
Basic naproxen sodium patents	Expired
Current pediatric exclusivity	Not a general market barrier
Current orphan exclusivity	Not applicable to ordinary naproxen products
Formulation-specific exclusivity	Possible only for a particular approved product and period
OTC monograph protection	Regulatory framework, not brand exclusivity

A sponsor can still obtain patents on a new formulation, delivery system, combination, or method of use. Those rights would protect the specific innovation, not naproxen as a molecule.

Which companies are challenging naproxen patents?

The market has no single active patent dispute that defines ordinary naproxen generic entry. Generic competition has historically involved major ANDA manufacturers, private-label suppliers, and vertically integrated pharmaceutical companies. Depending on product and jurisdiction, competitors may include Teva, Viatris, Sandoz, Dr. Reddy's, Lupin, Perrigo, Hikma, and other generic manufacturers.

Paragraph IV risk is product-specific. A company developing a newly patented naproxen formulation could receive an ANDA Paragraph IV certification from a generic sponsor. That would create possible Hatch-Waxman litigation and, if timely sued, a potential 30-month stay under the statutory framework.[3] For conventional naproxen tablets and naproxen sodium tablets, the practical risk is ordinary generic price competition rather than a dispute over core molecule patents.

What naproxen formulation patents and litigation issues matter?

The main litigation exposure for a differentiated naproxen product would arise from four areas:

1. A formulation patent covering a specific excipient matrix, particle architecture, or release profile.
2. A method-of-use patent covering an approved dosing regimen or patient population.
3. A manufacturing patent covering a non-routine process that is practiced by the generic manufacturer.
4. A combination-product patent covering naproxen with another active ingredient.

Method-of-use patents can be difficult to enforce when the product has broad pain indications and physicians prescribe generically. Carve-out labeling may reduce infringement exposure for some indications, but it does not eliminate commercial substitution risk.

Settlement agreements are not a central feature of the mature conventional naproxen market. A settlement becomes more relevant if a sponsor launches a protected extended-release, pediatric, combination, or specialty formulation with substantial sales.

How strong is the naproxen patent estate?

The molecule-level estate is weak because the core rights are expired. A new naproxen product can still have a strong product-level estate if it combines:

• A clinically meaningful release profile
• A difficult-to-reproduce particle or polymer architecture
• Demonstrated pharmacokinetic advantages
• A specific patient population
• A manufacturing process that competitors cannot easily replicate
• Several patent families with independent claim scope

The weakest strategy is a conventional immediate-release tablet using standard excipients with no distinct dissolution or clinical profile. The strongest strategy is a formulation platform that produces a measurable benefit and supports multiple claim types.

What are the main commercial opportunities in naproxen?

Premium OTC positioning

The OTC market can support products positioned around:

• Faster perceived onset
• Easier swallowing
• Lower pill burden
• Better taste
• Arthritis and overnight symptom control
• Travel-friendly packaging
• Unit-dose blister formats

Claims must remain consistent with FDA labeling and supported by appropriate evidence. A premium price is difficult to sustain without a visible consumer benefit.

Pediatric and dysphagia formulations

Liquid, chewable, mini-tablet, and orally disintegrating products can address underserved administration needs. Pediatric formulations require careful dose flexibility and palatability work. A syringe-compatible suspension with reliable redispersion can have stronger practical value than a new conventional tablet.

Once-daily extended release

Extended release can support prescription or specialty OTC positioning. The commercial opportunity depends on adherence improvement and clinically relevant dosing convenience. The product must avoid a formulation that merely delays exposure without improving patient outcomes or use patterns.

Combination products

Naproxen combinations with gastric-protection agents, migraine therapies, muscle relaxants, or other analgesics may create commercial differentiation. Risks include added clinical development, drug-drug interaction analysis, fixed-dose dose flexibility limitations, and potentially larger tablet size.

Manufacturing and supply-chain differentiation

In a low-price generic market, cost and supply reliability can be more valuable than a narrow patent. Opportunities include:

• Direct-compression formulations with high tablet throughput
• Low-dust micronized active handling
• Continuous manufacturing
• Reduced solvent or water use
• Stable formulations suitable for multiple climates
• Fewer excipient suppliers
• Improved tablet coating efficiency

How does naproxen compare with ibuprofen and diclofenac?

Attribute	Naproxen	Ibuprofen	Diclofenac
Market maturity	Highly generic	Highly generic	Highly generic
Main formulation challenge	Low solubility and dose size	Low solubility and dose flexibility	Solubility, stability, and dosage-form diversity
Common fast-onset strategy	Naproxen sodium	Ibuprofen salts or liquid systems	Specialized salts and release systems
OTC presence	Strong	Very strong	More limited in some markets
Extended-release opportunity	Meaningful	Meaningful	Meaningful
Biosimilar risk	None	None	None
Core patent barrier	Expired	Expired	Expired
Differentiation potential	Pediatric, ER, taste, combination	Pediatric, liquid, rapid release	Topical, enteric, modified release

Naproxen has a longer dosing interval than some NSAID regimens, which supports extended-release and adherence-oriented positioning. Ibuprofen has broader consumer familiarity and more dosage-form variety. Diclofenac has stronger topical and specialty formulation opportunities in many markets.

What generic launch risks exist for a new naproxen product?

A generic or reformulated naproxen launch faces five principal risks:

• Price erosion from numerous ANDA suppliers
• Failure to show bioequivalence for a modified-release or complex product
• Dissolution differences caused by salt form, particle size, or lubrication
• Limited physician or consumer willingness to pay a premium
• FDA scrutiny of NSAID labeling, dosing, cardiovascular risk, and gastrointestinal warnings

The best launch candidates are products with a clear administration advantage, a clinically relevant exposure profile, or a supply-chain cost advantage. A conventional 250 mg, 375 mg, or 500 mg tablet has limited room for differentiation.

Key Takeaways

• Naproxen is a mature, fully generic small-molecule NSAID with expired core exclusivity.
• Naproxen sodium is preferred for faster dissolution and immediate-release positioning.
• The most important excipient issues are wetting, disintegration, lubrication, taste masking, and release control.
• Conventional filler-disintegrant formulations have weak patent potential.
• Solid dispersions, multiparticulates, extended-release systems, stable suspensions, and pediatric dosage forms offer stronger differentiation.
• FDA approval follows the small-molecule NDA or ANDA framework; biosimilar competition does not apply.
• Commercial opportunity is concentrated in premium OTC products, pediatric and dysphagia formats, once-daily delivery, combination products, and manufacturing efficiency.
• Paragraph IV litigation is mainly relevant to a newly patented formulation, not to ordinary naproxen tablets.
• A defensible patent estate should link excipient architecture to measurable dissolution, stability, pharmacokinetic, clinical, or manufacturing performance.

FAQs

Can naproxen be formulated as an orally disintegrating tablet?

Yes. Mannitol, crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, taste-masking polymers, and coated drug particles can support an orally disintegrating product. Bitter taste and the relatively high dose are the main development constraints.

Is naproxen sodium better than naproxen for fast pain relief?

Naproxen sodium generally dissolves faster than naproxen free acid and is commonly used for faster-onset immediate-release products. Clinical onset also depends on dose, formulation, gastric emptying, food, and individual pharmacokinetics.

Which excipients are most likely to improve naproxen dissolution?

Superdisintegrants, surfactants, wetting agents, particle-size control, polymeric dispersion carriers, and selected lipid systems are the main options. The optimal approach depends on whether the target is a low-cost tablet, liquid-filled capsule, suspension, or modified-release product.

Can a new naproxen excipient combination receive patent protection?

Yes, but routine combinations of standard excipients are difficult to protect. Patentability improves when the formulation has a defined composition and produces an unexpected dissolution, stability, taste, pharmacokinetic, or manufacturing result.

Does naproxen have biosimilar competition?

No. Naproxen is a chemically synthesized small molecule. Competition occurs through generic drug applications, branded generics, OTC products, and reformulated products rather than the FDA biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs

4. U.S. Food and Drug Administration. (2022). Naproxen sodium drug products for over-the-counter human use: Final monograph framework. 21 C.F.R. Part 343.

5. U.S. Food and Drug Administration. (2017). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/waiver-vivo-bioavailability-and-bioequivalence-studies-immediate-release-solid-oral-dosage-forms-0